Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Midsummer | Main | Vivus, Qnexa, Arena, Lorcaserin and the FDA »

July 22, 2010

Back in Business

Email This Entry

Posted by Derek

I wanted to let everyone know that I'm back from my break, and will resume regular blogging tomorrow. I have a few topics queued up, but in case I've missed something - any big stories out there that we should be talking about?

Comments (20) + TrackBacks (0) | Category: Blog Housekeeping


COMMENTS

1. newnickname on July 22, 2010 1:50 PM writes...

Another link for the "Natural Products: Not the Best Fit for Drugs?" topic from Jul 12, 2010.

Bioactivity-Guided Navigation of Chemical Space.
Robin S. Bon and Herbert Waldmann. Acc. Chem. Res., May 19, 2010, DOI: 10.1021/ar100014h

A central aim of biological research is to elucidate the many roles of proteins in complex, dynamic living systems; the selective perturbation of protein function is an important tool in achieving this goal. Because chemical perturbations offer opportunities often not accessible with genetic methods, the development of small-molecule modulators of protein function is at the heart of chemical biology research. In this endeavor, the identification of biologically relevant starting points within the vast chemical space available for the design of compound collections is a particularly relevant, yet difficult, task.

In this Account, we present our research aimed at linking chemical and biological space to define suitable starting points that guide the synthesis of compound collections with biological relevance.

Permalink to Comment

2. Anonymous on July 22, 2010 4:18 PM writes...

I have always wondered what the scientific community on this blog thinks about this process (http://www.georgetownuniversityhospital.org/body_press.cfm?id=15&UserAction=PressDetails&action=detail&ref=207) which has been proposed as a possible treatment for multiple sclerosis. I believe it was first proposed/discovered by an Italian doctor and is now being explored as an alternative to drug therapies.

Permalink to Comment

3. Don Monroe on July 22, 2010 4:21 PM writes...

Avastin. Probably you're on that already, though.
Welcome back.

Permalink to Comment

4. cynical1 on July 22, 2010 5:08 PM writes...

Anon #2: I would not hold your breath on that one. I have extensive experience in multiple sclerosis research and clinical development. I think the NMSS is going to waste a lot of money on this red herring.

Permalink to Comment

5. Bluto Blutarsky on July 22, 2010 6:20 PM writes...

The layoffs at Sanofi-Aventis. I recently heard about some former colleagues who had significant amount of service (20+ years) with Aventis/Rhone-Poulenc Rorer/Rorer (anyone remember them?) who got the axe there....

Permalink to Comment

6. Mike on July 22, 2010 6:25 PM writes...

Glad you're back! I was missing this blog. I always enjoy your entries, even coming as I do from a non-chemisty background. If you've heard of any horrifying new chemicals you won't work with, or any ridiculous horror stories of laboratory ineptitude those are always a welcome treat :)

Permalink to Comment

7. bbooooooya on July 22, 2010 6:39 PM writes...

VVUS ad panel!

Apparently 1 yr safety, which was worth SPA from FDA, did not merit thumbs up from ad panel.

Interesting to see how plays out on oct 22, and what happens to arna on sept 16.

too bad you can't bottle exercise and sensible eating.

Permalink to Comment

8. Mr E chemist on July 22, 2010 7:28 PM writes...

Bluto #5 , I am a former Rorer chemist now at another pharma, many friends and former colleagues at Sanofi-Aventis? How bad was it , did medchem get hit hard?

Permalink to Comment

9. biochap on July 22, 2010 10:43 PM writes...

Lilly CEO: Pipeline to soften patent losses

Permalink to Comment

10. Knight on July 23, 2010 2:27 AM writes...

PPARgamma ligand and cdk5
Nature doi:10.1038/nature09291

Permalink to Comment

11. befuddled on July 23, 2010 5:19 AM writes...

I second #10 on the PPARgamma ligand connection with CDK5 phosphorylation. One question that came to mind reading about that research: how good are the mouse models of diabetes?

@2: The NY Times had a good long article on this:
www.nytimes.com/2010/06/29/health/29vein.html

One disturbing quote from the article:
"On June 29, the team in Buffalo is to begin the first treatment study to include a control group. The controls will be given a sham procedure, and compared with others who get the real thing. Initially, 30 patients — only those with an early form of the disease — will be enrolled."

So, despite all the hullabaloo, *noone* had done a study with a control group? For a disease whose progression is so sporadic, that seems crazy.

I'm skeptical about both the theory and the treatment, but I have to say that this is the kind of alternative medicine that merits research simply because patients are using it already regardless of the scientific evidence.

Permalink to Comment

12. retread on July 23, 2010 9:24 AM writes...

I'd be interested in the opinions of the readership on the latest (organic, Pchem, NMR, biochemistry, molecular biology etc. etc.) textbooks. It took me quite a while to find an organometallic textbook which put the disposition in space of the d orbitals of the metals front and center.

Permalink to Comment

13. Anonymous on July 23, 2010 10:29 AM writes...

How about the following news shared at the International AIDS conference this week?

http://www.sciencemag.org/hottopics/hivprevention/index.dtl

Permalink to Comment

14. Jingle on July 23, 2010 10:35 AM writes...

Generic enoxaparin.

I think the pond just got broader - to my rather untrained eye, this looks like the EU is continuing to treat it as a biologic (because it's so irregular and comes from biologic source materials), while the US 505j approach potentially means more of a small molecule approach...but other than the LWMHs, what else falls between these two stools?

Permalink to Comment

15. Anonymous on July 23, 2010 12:18 PM writes...

To Senator Blutarsky and Mr. E Chemist:

This is what I've heard regarding S-A: pilot plant closing by end of 2010 - 30 chemists losing their jobs. Medicinal chemistry is losing ~20 chemists (out of ~75 total) - from very experienced to newbies (must balance it out to make it look good, you know). All told, ~50 scientists being displaced at Bridgewater - with a hint that Bridgewater might not be in management's plan past 2015.

Permalink to Comment

16. Anonymous on July 23, 2010 12:24 PM writes...

Do an entry on the scientist at Duke who got suspended for faking a Rhodes scholarship (I think) on his biosketch et al and publishing very questionable findings. Brings up the whole issue of nobody actively patrolling BS science because there's no upside.

Permalink to Comment

17. MIMD on July 24, 2010 7:32 AM writes...

On Duke, see post here.

Permalink to Comment

18. Anonymous on July 26, 2010 8:38 AM writes...

This was a great post & quote from Pharmalot last week:

"Not a good side effect for people paid to carry guns."

http://www.pharmalot.com/2010/07/chantix-and-violence-what-patients-have-in-common/

Permalink to Comment

19. Lavone Chirco on March 1, 2012 2:20 PM writes...

Today, with the fast lifestyle that everyone is having, credit cards have a huge demand in the economy. Persons from every area are using credit card and people who not using the credit card have prepared to apply for one in particular. Thanks for sharing your ideas on credit cards.

Permalink to Comment

20. food and art on May 8, 2012 5:23 PM writes...

Computer drives are much better at reading CD-R than stand alone DVD players. DVD players are more likely to produce glitches in the picture, but on a computer these errors are corrected.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
A Last Summer Day Off
The Early FDA
Drug Repurposing
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought